WO2020047103A1 - Methods and compositions for treating neuroblastoma in a juvenile mammalian body - Google Patents

Methods and compositions for treating neuroblastoma in a juvenile mammalian body Download PDF

Info

Publication number
WO2020047103A1
WO2020047103A1 PCT/US2019/048579 US2019048579W WO2020047103A1 WO 2020047103 A1 WO2020047103 A1 WO 2020047103A1 US 2019048579 W US2019048579 W US 2019048579W WO 2020047103 A1 WO2020047103 A1 WO 2020047103A1
Authority
WO
WIPO (PCT)
Prior art keywords
taurolidine
administered
neuroblastoma
nanoparticle
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/048579
Other languages
French (fr)
Inventor
Bruce Reidenberg
Robert Diluccio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Priority to EP19855576.5A priority Critical patent/EP3843745A4/en
Priority to JP2021511655A priority patent/JP7530351B2/en
Priority to CA3111015A priority patent/CA3111015A1/en
Priority to KR1020217008970A priority patent/KR102904381B1/en
Priority to AU2019330831A priority patent/AU2019330831B2/en
Priority to CN201980071376.2A priority patent/CN113164491A/en
Publication of WO2020047103A1 publication Critical patent/WO2020047103A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)

Definitions

  • This invention relates to therapeutic methods and compositions in general, and more particularly to therapeutic methods and compositions for the treatment of neuroblastoma in a juvenile mammalian body.
  • NB Neuroblastoma
  • neuroblastoma extracranial solid cancer in childhood, and the most common cancer in infancy, with an incidence of about six hundred fifty cases per year in the U.S., and a hundred cases per year in the UK. Nearly half of neuroblastoma cases occur in children younger than two years. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system (SNS) . Neuroblastoma most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. Note that while neuroblastoma arises from nerve tissues, it is not a tumor of the central nervous system ( CNS ) .
  • CNS central nervous system
  • Neuroblastoma is one of the few human
  • Neuroblastoma is a disease exhibiting extreme heterogeneity, and is stratified into three risk categories: low-risk, intermediate-risk, and high- risk. Low-risk neuroblastoma is most common in infants and good outcomes are common with observation only or surgery, whereas high-risk neuroblastoma is difficult to treat successfully even with the most intensive multi-modal therapies available.
  • therapy e.g., intensive chemotherapy, surgery, radiation therapy, stem cell transplant,
  • differentiation agent isotrentinoin (also called 13- cis-retinoic acid) , and frequently immunotherapy with anti-GD2 immunotherapy with anti-GD2 monoclonal antibody therapy.
  • High-risk neuroblastoma is generally treated with intensive chemotherapy, surgery, radiation therapy, bone marrow/hematopoietic stem cell transplantation, biological-based therapy with 13-cis-retinoic acid (isotretinoin or Accutane) and antibody therapy
  • cytokines GM-CSF and IL-2. cytokines
  • Chemotherapy agents used in combination have been found to be effective against neuroblastoma. Agents commonly used in induction and for stem cell
  • transplant conditioning are platinum compounds
  • topoisomerase I inhibitors topotecan and irinotecan in induction which have been found to be effective against recurrent disease.
  • taurolidine is used to treat neuroblastoma in juvenile mammalian bodies.
  • the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, and preferably with a dosage range of between 5 mg/kg and 60 mg/kg.
  • This dosage is administered from once daily through weekly for an effective period of time based on individual patient response.
  • the taurolidine is delivered systemically, preferably either intravenously (more preferred) or intramuscularly .
  • the taurolidine is delivered systemically in a "shielded form" so that hydrolysis of the taurolidine is delayed until the taurolidine reaches the site of the
  • the taurolidine may be delivered as a single agent or in combination with one or more oncolytic agents and/or radiotherapy.
  • a method for treating neuroblastoma in juvenile mammals comprising administering taurolidine to the juvenile mammal.
  • the taurolidine is administered with a dosage range of from 5 mg/kg to 280 mg/kg, for an effective period of time, based on individual patient response.
  • the taurolidine is administered with a dosage range of from 5 mg/kg and 60 mg/kg.
  • the dosage is administered from once daily through weekly.
  • the taurolidine is administered systemically .
  • the taurolidine is administered intravenously.
  • the taurolidine is administered intramuscularly.
  • the taurolidine is included in a nanoparticle, and the nanoparticle is configured to delay hydrolysis of the taurolidine until the nanoparticle reaches the site of a tumor.
  • the taurolidine is included in a nanoparticle, the nanoparticle comprises a taurolidine core and an exterior coating, and the exterior coating is configured to prevent exposure of the taurolidine prior to arrival of the nanoparticle at the site of the tumor.
  • the taurolidine is included in a nanoparticle, the nanoparticle comprises a taurolidine core and an exterior coating, and the exterior coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
  • the taurolidine is delivered using a polymer system which is configured to delay hydrolysis of the taurolidine.
  • the taurolidine is delivered using a polymer system, with the taurolidine being “pegylated” using polyethylene glycols (PEGs) to delay premature of hydrolysis of taurolidine.
  • PEGs polyethylene glycols
  • the taurolidine is administered to humans. In one form of the invention, the taurolidine is administered to at least one from the group consisting of infants, children and adolescents.
  • the taurolidine is administered as a single agent.
  • the taurolidine is administered in combination with at least one
  • the taurolidine is administered in combination with at least one
  • the at least one oncolytic agent is selected from the group consisting of platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan,
  • the taurolidine is administered in combination with radiotherapy.
  • Fig. 1 is a graph showing that leukemia cell lines appear more sensitive to the effects of
  • taurolidine compared to healthy lymphocytes in vitro ( not in vivo ) ;
  • Fig. 2 is a graph showing that neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
  • Figs. 3-6 are graphs or photographs showing that taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice has efficacy in
  • Figs. 7 and 8 are graphs showing that
  • Taurolidine is a well known antimicrobial with a published mechanism of action and antimicrobial spectrum. Taurolidine is unstable in circulation and therefore has not been successfully developed for systemic infections. Taurolidine has demonstrated efficacy in local application for peritonitis and for prevention of infection when infused as a catheter- lock solution.
  • Taurolidine has recently been investigated for oncolytic activity and found to have inhibitory effect on cell lines in culture, in combination with standard chemotherapy or alone. Despite claims that in vitro inhibitory concentrations are clinically achievable, the only published human pharmacokinetic study showed NO measurable concentration of taurolidine in healthy volunteers when 5 grams of taurolidine were given intravenously by 20 minute infusion. This is believed to be due to the rapid hydrolysis of taurolidine when administered systemically in a mammalian body.
  • neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
  • taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice showed efficacy in IMR5 tumors and measurable efficacy in SK- N-AS tumors in vivo (not in vitro) . See Figs. 3-6.
  • taurolidine may be used to treat neuroblastoma in a juvenile mammalian body .
  • the taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, and preferably with a dosage range of between 5 mg/kg and 60 mg/kg.
  • Effective dosage was computed by computing the human equivalent dosage from the effective mouse dose, using the following formula:
  • This dosage is administered from once daily through weekly for an effective period of time based on individual patient response.
  • the taurolidine is delivered systemically, preferably either intravenously (more preferred) or intramuscularly.
  • intravenously more preferred
  • intramuscularly preferably either intravenously (more preferred) or intramuscularly.
  • the taurolidine is delivered systemically in a "shielded form" so that hydrolysis of the
  • taurolidine is delayed until the taurolidine reaches the site of the neuroblastoma, whereupon hydrolysis of the taurolidine occurs.
  • the taurolidine is delivered in the form of a nanoparticle, where the nanoparticle comprises a taurolidine core and an exterior coating which is configured to prevent premature exposure of the taurolidine prior to the arrival of the nanoparticle to the tumor site.
  • the exterior coating breaks down as the nanoparticle travels from the site of insertion to the site of the tumor so as to release the taurolidine for hydrolysis at the site of the tumor.
  • the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
  • the coating can be created from combinations of copolymers and multimers derived from polymers structured from 1-lactide, glycolide, e- caprolactone, p-dioxanone, and trimethylene carbonate.
  • the coating may also be associated with glycols such as polyethylene glycols (PEGs), which can either be linear or multi-arm structures.
  • PEGs polyethylene glycols
  • the nanoparticle may comprise an excipient (e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine within the nanoparticle) .
  • an excipient e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine within the nanoparticle
  • the nanoparticle can further comprise a coating, wherein the coating is configured to target the nanoparticle to the site of a neuroblastoma so as to improve the efficacy of the taurolidine for treatment of the neuroblastoma.
  • the coating comprises binding molecules which are configured to target delivery of the nanoparticle to specific tissue.
  • the coating for the nanoparticle comprises a monoclonal antibody against N-type calcium channels (e.g., an anti-N-type calcium channel exofacial Fab fragment) for causing the nanoparticle to bind to neural tissue (e.g., to a neuroblastoma tumor) .
  • the taurolidine may be delivered using a polymer system which is configured to delay hydrolysis of the taurolidine and/or optimize the release properties of the
  • taurolidine may be “pegylated” using polyethylene glycols (PEGs) to delay premature of hydrolysis of taurolidine and/or optimize the release properties of the taurolidine.
  • PEGs polyethylene glycols
  • the taurolidine may be delivered as a single agent or in combination with one or more oncolytic agents and/or radiotherapy.
  • oncolytic agents that can be combined with taurolidine for delivery to a juvenile mammal for treating
  • neuroblastoma are platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan, topoisomerase II inhibitor), vinca alkaloids (vincristine), and topoisomerase I inhibitors (topotecan and irinotecan) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals.

Description

METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA
IN A JUVENILE MAMMALIAN BODY
Applicant
CorMedix Inc.
Inventors
Bruce Reidenberg
Robert DiLuccio
Reference To Pending Prior Patent Applications
This patent application:
(i) is a continuation-in-part of pending prior U.S. Patent Application Serial No. 15/403,876, filed 01/11/2017 by CorMedix Inc. and Robert DiLuccio for THERAPEUTIC NANOPARTICLES FOR THE TREATMENT OF NEUROBLASTOMA AND OTHER CANCERS (Attorney's Docket No. CORMEDIX-14 ) , which patent application claims benefit of prior U.S. Provisional Patent Application Serial No. 62/277,243, filed 01/11/2016 by CorMedix Inc. and
Robert DiLuccio for NANOPARTICLE SYSTEM FOR THE TREATMENT OF NEUROBLASTOMA (Attorney's Docket No.
CORMEDIX-14 PROV) ; and
(ii) claims benefit of pending prior U.S.
Provisional Patent Application Serial No. 62/723,592, filed 08/28/2018 by CorMedix Inc. and Bruce Reidenberg et al. for METHODS AND COMPOSITIONS FOR TREATING
NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY (Attorney's Docket No. CORMEDIX-32 PROV) .
The three (3) above-identified patent
applications are hereby incorporated herein by
reference .
Field Of The Invention
This invention relates to therapeutic methods and compositions in general, and more particularly to therapeutic methods and compositions for the treatment of neuroblastoma in a juvenile mammalian body.
Background Of The Invention
Neuroblastoma (NB) is the most common
extracranial solid cancer in childhood, and the most common cancer in infancy, with an incidence of about six hundred fifty cases per year in the U.S., and a hundred cases per year in the UK. Nearly half of neuroblastoma cases occur in children younger than two years. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system (SNS) . Neuroblastoma most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis. Note that while neuroblastoma arises from nerve tissues, it is not a tumor of the central nervous system ( CNS ) .
Neuroblastoma is one of the few human
malignancies known to demonstrate spontaneous
regression from an undifferentiated state to a
completely benign cellular appearance.
Neuroblastoma is a disease exhibiting extreme heterogeneity, and is stratified into three risk categories: low-risk, intermediate-risk, and high- risk. Low-risk neuroblastoma is most common in infants and good outcomes are common with observation only or surgery, whereas high-risk neuroblastoma is difficult to treat successfully even with the most intensive multi-modal therapies available.
When the neuroblastoma lesion is localized, it is generally curable. However, long-term survival for children older than 18 months of age with advanced disease is poor, despite aggressive multimodal
therapy, e.g., intensive chemotherapy, surgery, radiation therapy, stem cell transplant,
differentiation agent isotrentinoin (also called 13- cis-retinoic acid) , and frequently immunotherapy with anti-GD2 immunotherapy with anti-GD2 monoclonal antibody therapy.
Biologic and genetic characteristics have been identified which, when added to classic clinical staging, has allowed patient assignment to risk groups for planning treatment intensity. These criteria include age of the patient, extent of disease spread, microscopic appearance, and genetic features including DNA ploidy and N-myc oncogene amplification (N-myc regulate micro RNAs) . These criteria are used to classify the neuroblastoma into low-risk, intermediate-risk, and high-risk disease. A recent biology study (COG ANBL00B1) analyzed 2,687
neuroblastoma patients and the spectrum of risk assignment was determined: 37% of neuroblastoma cases are low-risk, 18% of neuroblastoma cases are
intermediate-risk, and 45% of neuroblastoma cases are high-risk. Note that there is some evidence that the high-risk and low-risk types of neuroblastoma are caused by different mechanisms, and are not merely two different degrees of expression of the same mechanism.
The therapies for these different risk categories are very different.
Low-risk neuroblastoma can frequently be observed without any treatments at all or cured with surgery alone .
Intermediate-risk neuroblastoma is generally treated with surgery and chemotherapy.
High-risk neuroblastoma is generally treated with intensive chemotherapy, surgery, radiation therapy, bone marrow/hematopoietic stem cell transplantation, biological-based therapy with 13-cis-retinoic acid (isotretinoin or Accutane) and antibody therapy
(usually administered with the cytokines GM-CSF and IL-2. cytokines) .
With current treatments, patients with low-risk neuroblastoma and intermediate-risk neuroblastoma have an excellent prognosis, with cure rates above 90% for low-risk neuroblastoma and 70-90% cure rates for intermediate-risk neuroblastoma. In contrast, therapy for high-risk neuroblastoma over the past two decades has resulted in cures only about 30% of the time. The addition of antibody therapy has raised survival rates for high-risk neuroblastoma significantly. In March 2009, an early analysis of a Children's Oncology Group (COG) study with 226 high-risk neuroblastoma patients showed that two years after stem cell transplant, 66% of the group randomized to receive chl4.18 antibody with GM-CSF and IL-2 were alive and disease-free, compared to only 46% in the group that did not receive the antibody. The randomization was stopped so all patients enrolling in the trial could receive the antibody therapy.
Chemotherapy agents used in combination have been found to be effective against neuroblastoma. Agents commonly used in induction and for stem cell
transplant conditioning are platinum compounds
(cisplatin, carboplatin) , alkylating agents
(cyclophosphamide, ifosfamide, melphalan,
topoisomerase II inhibitor) and vinca alkaloids
(vincristine) . Some newer regimens include
topoisomerase I inhibitors (topotecan and irinotecan) in induction which have been found to be effective against recurrent disease.
However, a need exists for a new method and composition which are effective against neuroblastoma in a juvenile mammalian body.
Summary Of The Invention
In accordance with the present invention, taurolidine is used to treat neuroblastoma in juvenile mammalian bodies. The taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, and preferably with a dosage range of between 5 mg/kg and 60 mg/kg.
This dosage is administered from once daily through weekly for an effective period of time based on individual patient response.
The taurolidine is delivered systemically, preferably either intravenously (more preferred) or intramuscularly .
In one preferred form of the invention, the taurolidine is delivered systemically in a "shielded form" so that hydrolysis of the taurolidine is delayed until the taurolidine reaches the site of the
neuroblastoma, whereupon hydrolysis of the taurolidine occurs .
The taurolidine may be delivered as a single agent or in combination with one or more oncolytic agents and/or radiotherapy.
In one form of the invention, there is provided a method for treating neuroblastoma in juvenile mammals the method comprising administering taurolidine to the juvenile mammal.
In one form of the invention, the taurolidine is administered with a dosage range of from 5 mg/kg to 280 mg/kg, for an effective period of time, based on individual patient response.
In one form of the invention, the taurolidine is administered with a dosage range of from 5 mg/kg and 60 mg/kg.
In one form of the invention, the dosage is administered from once daily through weekly.
In one form of the invention, the taurolidine is administered systemically .
In one form of the invention, the taurolidine is administered intravenously.
In one form of the invention, the taurolidine is administered intramuscularly.
In one form of the invention, the taurolidine is included in a nanoparticle, and the nanoparticle is configured to delay hydrolysis of the taurolidine until the nanoparticle reaches the site of a tumor. In one form of the invention, the taurolidine is included in a nanoparticle, the nanoparticle comprises a taurolidine core and an exterior coating, and the exterior coating is configured to prevent exposure of the taurolidine prior to arrival of the nanoparticle at the site of the tumor.
In one form of the invention, the taurolidine is included in a nanoparticle, the nanoparticle comprises a taurolidine core and an exterior coating, and the exterior coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
In one form of the invention, the taurolidine is delivered using a polymer system which is configured to delay hydrolysis of the taurolidine.
In one form of the invention, the taurolidine is delivered using a polymer system, with the taurolidine being "pegylated" using polyethylene glycols (PEGs) to delay premature of hydrolysis of taurolidine.
In one form of the invention, the taurolidine is administered to humans. In one form of the invention, the taurolidine is administered to at least one from the group consisting of infants, children and adolescents.
In one form of the invention, the taurolidine is administered as a single agent.
In one form of the invention, the taurolidine is administered in combination with at least one
oncolytic agent.
In one form of the invention, the taurolidine is administered in combination with at least one
oncolytic agent, and the at least one oncolytic agent is selected from the group consisting of platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan,
topoisomerase II inhibitor), vinca alkaloids
(vincristine), and topoisomerase I inhibitors
(topotecan and irinotecan) .
In one form of the invention, the taurolidine is administered in combination with radiotherapy.
Brief Description Of The Drawings These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:
Fig. 1 is a graph showing that leukemia cell lines appear more sensitive to the effects of
taurolidine compared to healthy lymphocytes in vitro ( not in vivo ) ;
Fig. 2 is a graph showing that neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
fibroblasts (BJ on graph) in vitro (not in vivo);
Figs. 3-6 are graphs or photographs showing that taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice has efficacy in
IMR5 tumors and measurable efficacy in SK-N-AS tumors in vivo (not in vitro) ; and Figs. 7 and 8 are graphs showing that
statistically significant decreases in tumor size were achieved when taurolidine was administered to treat mice with a different cell line (SK-N-AS) also derived from neuroblastoma but overall survival was not significantly different from control.
Detailed Description Of The Invention
Taurolidine is a well known antimicrobial with a published mechanism of action and antimicrobial spectrum. Taurolidine is unstable in circulation and therefore has not been successfully developed for systemic infections. Taurolidine has demonstrated efficacy in local application for peritonitis and for prevention of infection when infused as a catheter- lock solution.
Taurolidine has recently been investigated for oncolytic activity and found to have inhibitory effect on cell lines in culture, in combination with standard chemotherapy or alone. Despite claims that in vitro inhibitory concentrations are clinically achievable, the only published human pharmacokinetic study showed NO measurable concentration of taurolidine in healthy volunteers when 5 grams of taurolidine were given intravenously by 20 minute infusion. This is believed to be due to the rapid hydrolysis of taurolidine when administered systemically in a mammalian body.
It has been found that leukemia cell lines appear more sensitive to the effects of taurolidine compared to healthy lymphocytes in vitro (not in vivo) . See Fig. 1.
It has also been found that neuroblastoma cell lines are more sensitive to a decrease in viability due to taurolidine when compared to healthy
fibroblasts in vitro (not in vivo) . See Fig. 2.
Furthermore, taurolidine given to CB57 SCID mice with measurable tumors from a neuroblastoma cell line implanted subcutaneously in the CB57 SCID mice showed efficacy in IMR5 tumors and measurable efficacy in SK- N-AS tumors in vivo (not in vitro) . See Figs. 3-6.
Statistically significant decreases in tumor size were achieved when taurolidine was administered to treat mice with a different cell line (SK-N-AS) also derived from neuroblastoma, though overall survival of the mice implanted with the tumor was not
statistically different from the control. See Figs. 7 and 8.
It has now been discovered that taurolidine may be used to treat neuroblastoma in a juvenile mammalian body .
The taurolidine is given with a dosage range of from 5 mg/kg to 280 mg/kg, and preferably with a dosage range of between 5 mg/kg and 60 mg/kg.
Effective dosage was computed by computing the human equivalent dosage from the effective mouse dose, using the following formula:
Human equivalent dose = mouse mg/kg dose x 1 adult human/12 mice x 25 child BSA ratio/37 adult BSA ratio = child dose in mg/kg
( https : / /www . fda . gov/downloads /drugs /guidances /ucmO 789
32.pdf) . This dosage is administered from once daily through weekly for an effective period of time based on individual patient response.
The taurolidine is delivered systemically, preferably either intravenously (more preferred) or intramuscularly. In one preferred form of the
invention, the taurolidine is delivered systemically in a "shielded form" so that hydrolysis of the
taurolidine is delayed until the taurolidine reaches the site of the neuroblastoma, whereupon hydrolysis of the taurolidine occurs.
More particularly, in one preferred form of the invention, the taurolidine is delivered in the form of a nanoparticle, where the nanoparticle comprises a taurolidine core and an exterior coating which is configured to prevent premature exposure of the taurolidine prior to the arrival of the nanoparticle to the tumor site. The exterior coating breaks down as the nanoparticle travels from the site of insertion to the site of the tumor so as to release the taurolidine for hydrolysis at the site of the tumor.
In one preferred form of the invention, the coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor. By way of example but not limitation, the coating can be created from combinations of copolymers and multimers derived from polymers structured from 1-lactide, glycolide, e- caprolactone, p-dioxanone, and trimethylene carbonate. The coating may also be associated with glycols such as polyethylene glycols (PEGs), which can either be linear or multi-arm structures.
If desired, the nanoparticle may comprise an excipient (e.g., a buffer for providing enhanced hydrolytic stability of the taurolidine within the nanoparticle) .
Additionally, if desired, the nanoparticle can further comprise a coating, wherein the coating is configured to target the nanoparticle to the site of a neuroblastoma so as to improve the efficacy of the taurolidine for treatment of the neuroblastoma. In one preferred form of the invention, the coating comprises binding molecules which are configured to target delivery of the nanoparticle to specific tissue. By way of example but not limitation, the coating for the nanoparticle comprises a monoclonal antibody against N-type calcium channels (e.g., an anti-N-type calcium channel exofacial Fab fragment) for causing the nanoparticle to bind to neural tissue (e.g., to a neuroblastoma tumor) .
In another form of the invention, the taurolidine may be delivered using a polymer system which is configured to delay hydrolysis of the taurolidine and/or optimize the release properties of the
taurolidine. By way of example but not limitation, the taurolidine may be "pegylated" using polyethylene glycols (PEGs) to delay premature of hydrolysis of taurolidine and/or optimize the release properties of the taurolidine.
The taurolidine may be delivered as a single agent or in combination with one or more oncolytic agents and/or radiotherapy. Examples of oncolytic agents that can be combined with taurolidine for delivery to a juvenile mammal for treating
neuroblastoma are platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan, topoisomerase II inhibitor), vinca alkaloids (vincristine), and topoisomerase I inhibitors (topotecan and irinotecan) .
Modifications
While the present invention has been described in terms of certain exemplary preferred embodiments, it will be readily understood and appreciated by those skilled in the art that it is not so limited, and that many additions, deletions and modifications may be made to the preferred embodiments discussed above while remaining within the scope of the present invention .

Claims

What Is Claimed Is:
1. A method for treating neuroblastoma in juvenile mammals, the method comprising administering taurolidine to the juvenile mammal.
2. A method according to claim 1 wherein the taurolidine is administered with a dosage range of from 5 mg/kg to 280 mg/kg, for an effective period of time, based on individual patient response.
3. A method according to claim 2 wherein the dosage range is from 5 mg/kg and 60 mg/kg.
4. A method according to claim 1 wherein the dosage is administered from once daily through weekly.
5. A method according to claim 1 wherein the taurolidine is administered systemically .
6. A method according to claim 5 wherein the taurolidine is administered intravenously.
7. A method according to claim 5 wherein the taurolidine is administered intramuscularly.
8. A method according to claim 5 wherein the taurolidine is included in a nanoparticle, and further wherein the nanoparticle is configured to delay hydrolysis of the taurolidine until the nanoparticle reaches the site of a tumor.
9. A method according to claim 8 wherein the nanoparticle comprises a taurolidine core and an exterior coating, wherein the exterior coating is configured to prevent exposure of the taurolidine prior to arrival of the nanoparticle at the site of the tumor .
10. A method according to claim 9 wherein the exterior coating comprises an absorbable polymer or lipid which breaks down as the nanoparticle travels from the site of insertion to the site of the tumor.
11. A method according to claim 5 wherein the taurolidine is delivered using a polymer system which is configured to delay hydrolysis of the taurolidine.
12. A method according to claim 11 wherein the taurolidine is "pegylated" using polyethylene glycols (PEGs) to delay premature of hydrolysis of
taurolidine .
13. A method according to claim 1 wherein the taurolidine is administered to humans.
14. A method according to claim 13 wherein the taurolidine is administered to at least one from the group consisting of infants, children and adolescents.
15. A method according to claim 1 wherein the taurolidine is administered as a single agent.
16. A method according to claim 1 wherein the taurolidine is administered in combination with at least one oncolytic agent.
17. A method according to claim 16 wherein the at least one oncolytic agent is selected from the group consisting of platinum compounds (cisplatin, carboplatin) , alkylating agents (cyclophosphamide, ifosfamide, melphalan, topoisomerase II inhibitor), vinca alkaloids (vincristine), and topoisomerase I inhibitors (topotecan and irinotecan) .
18. A method according to claim 1 wherein the taurolidine is administered in combination with radiotherapy .
PCT/US2019/048579 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a juvenile mammalian body Ceased WO2020047103A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP19855576.5A EP3843745A4 (en) 2018-08-28 2019-08-28 METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY
JP2021511655A JP7530351B2 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a young mammalian body - Patents.com
CA3111015A CA3111015A1 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a juvenile mammalian body
KR1020217008970A KR102904381B1 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in juvenile mammalian bodies
AU2019330831A AU2019330831B2 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a juvenile mammalian body
CN201980071376.2A CN113164491A (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in young mammals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862723592P 2018-08-28 2018-08-28
US62/723,592 2018-08-28

Publications (1)

Publication Number Publication Date
WO2020047103A1 true WO2020047103A1 (en) 2020-03-05

Family

ID=69645361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/048579 Ceased WO2020047103A1 (en) 2018-08-28 2019-08-28 Methods and compositions for treating neuroblastoma in a juvenile mammalian body

Country Status (7)

Country Link
EP (1) EP3843745A4 (en)
JP (1) JP7530351B2 (en)
KR (1) KR102904381B1 (en)
CN (1) CN113164491A (en)
AU (1) AU2019330831B2 (en)
CA (1) CA3111015A1 (en)
WO (1) WO2020047103A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130085469A1 (en) * 2004-02-03 2013-04-04 Hans-Dietrich Polaschegg Taurolidine formulations and delivery: therapeutic treatments and antimicrobial protection against bacterial biofilm formation
US9012444B2 (en) * 1999-06-04 2015-04-21 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US9844555B2 (en) * 2012-06-18 2017-12-19 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
EP1246617B1 (en) 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
ATE354380T1 (en) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te COMPOSITION FOR THE PREVENTION OF INFECTIONS THROUGH SUBCUTANEOUS PROSTHESIS
CN106974901A (en) * 2016-01-18 2017-07-25 贵州益佰制药股份有限公司 Application of the lobaplatin in treatment neuroblast tumor medicine is prepared
WO2018129061A1 (en) * 2017-01-05 2018-07-12 Cormedix Inc. Antimicrobial delivery system for the prevention and treatment of infections in the colon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012444B2 (en) * 1999-06-04 2015-04-21 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20130085469A1 (en) * 2004-02-03 2013-04-04 Hans-Dietrich Polaschegg Taurolidine formulations and delivery: therapeutic treatments and antimicrobial protection against bacterial biofilm formation
US9844555B2 (en) * 2012-06-18 2017-12-19 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3843745A4 *

Also Published As

Publication number Publication date
CA3111015A1 (en) 2020-03-05
EP3843745A1 (en) 2021-07-07
KR102904381B1 (en) 2025-12-31
AU2019330831B2 (en) 2025-10-30
CN113164491A (en) 2021-07-23
KR20210050543A (en) 2021-05-07
JP7530351B2 (en) 2024-08-07
EP3843745A4 (en) 2022-06-15
JP2021535173A (en) 2021-12-16
AU2019330831A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
Yin et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling
Moding et al. Strategies for optimizing the response of cancer and normal tissues to radiation
Quan et al. Brain metastases in small cell lung cancer
Salem et al. Proton radiation therapy: a systematic review of treatment-related side effects and toxicities
Amit et al. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
JP2024170590A (en) Treatment of neuroblastoma with taurolidine hydrolysis products
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
Suntharalingam et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT)
Lam et al. Understanding the Radiobiology of Central Nervous System Diseases in the Golden Age of Radiosurgery—Does It Matter?
CN115137748A (en) Mesoporous silica-cerium oxide-miR 129 composite material and preparation method and application thereof
AU2019330831B2 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
Lohiya et al. Novel chemotherapy modalities for different cancers
Sesink The molecular and cellular consequences of AsiDNA™ combined with radiotherapy on healthy tissue
JP2023549698A (en) Compositions of nanoparticles for the treatment of cancer
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
RU2013115739A (en) SDF-1 BINDING NUCLEIC ACIDS AND THEIR APPLICATION FOR TREATMENT OF CANCER
Ostanin Controlled Eosinophilic Syndrome Against Cancer. Scientific Discovery and Practical Aspects of Immunotherapy
Youssef Re-evaluating Brain Metastases Treatment and Outcomes in the Stereotactic Radiotherapy Era
Zhang et al. Research progresses on FLASH radiotherapy and its application for the treatment of digestive system tumors
Bell Radiobiological Investigations of Orthovoltage X-Rays, FLASH Proton Therapy, and Carbon Ion Radiotherapy
WO2026107242A1 (en) Ras and pd-1 or pd-l1 inhibitors combination therapy
JP2018514586A (en) Composition for the treatment of cancer
WO2020047530A1 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
McBride et al. Perez & Brady's Principles and Practice of Radiation Oncology (Perez and Bradys Principles and Practice of Radiation Oncology)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19855576

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3111015

Country of ref document: CA

Ref document number: 2021511655

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217008970

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019855576

Country of ref document: EP

Effective date: 20210329

ENP Entry into the national phase

Ref document number: 2019330831

Country of ref document: AU

Date of ref document: 20190828

Kind code of ref document: A